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Summary
Objective To investigate recent trends in the recorded incidence, lifetime
prevalence and prescribing of symptom relief medication for allergic rhinitis
in England.
Design Analysis of primary healthcare datasets.
Setting The UK prevalence of allergic rhinitis has increased very
significantly over recent decades. Analysis of primary healthcare datasets
offers the possibility to advance understanding about the changing
epidemiology and management of allergic rhinitis. QRESEARCH is one of the
world’s largest national aggregated health databases containing the records
of over nine million patients. We extracted data on all patients with a
recorded diagnosis of allergic rhinitis and calculated annual age–sex
standardized incidence and lifetime period prevalence rates for each year
from 2001–2005. We also analysed prescribing trends for antihistamines and
drugs used in nasal allergy in those with a recorded diagnosis of allergic
rhinitis.
Main outcome measures Age-sex standardized incidence, lifetime
prevalence rates and prescribing trends for symptom relief medication for
allergic rhinitis in England.
Results The age-sex standardized incidence of allergic rhinitis was
5.57 per 1000 person-years in 2001 and increased by 33.0% to 7.41 per 1000
person-years in 2005 (P<0.001). Lifetime age-sex standardized prevalence of
a recorded diagnosis of allergic rhinitis increased by 43.2% from 46.35 per
1000 in 2001 to 66.37 per 1000 in 2005 (P<0.001). Over this period a 41.7%
overall increase in prescriptions for antihistamines and drugs used in nasal
allergy was observed (antihistamines 45.5%, drugs used in nasal allergies
35.5%).
Conclusions Recorded incidence and lifetime prevalence of allergic
rhinitis have increased substantially in recent years. A similar increase in
prescriptions for antihistamines and drugs used in nasal allergy in patients
with allergic rhinitis is also observed.
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Introduction
Allergic rhinitis is a common condition affecting
people of all ages in the UK.1,2 A recent review of
existing UK epidemiological data revealed that
the prevalence of allergic rhinitis approximately
trebled over the last three decades, but more
recently appears to have stabilized, andmay in fact
be declining.3 The reasons underpinning these
variations in disease patterns remain poorly
understood.
The International Study of Asthma and
Allergies in Childhood (ISAAC) epidemiological
research programme recently published data of
their 2002–2003 Phase Three study;2 this survey
compared data from the baseline Phase One study
(completed a mean of seven years after Phase
One).4 Both phases of this international cross-
sectional survey enquired about symptoms indica-
tive of allergic rhinitis over a 12-month period in
school-aged children. Results showed that in the
UK, the 12-month period prevalence of self-
reported symptoms of allergic rhinitis was 15.3%
in 13–14 year-olds, a fall of 3.6% from Phase One.
In 6–7 year-olds, the 2002–2003 12-month preva-
lence of self reported symptoms was 10.1%, an
increase of 0.3% from Phase One.
In adults, data from the Health Survey for
England (HSE) found that the 12-month period
prevalence of symptoms was 15% in 2001, this
being unchanged from the 1996 figures.3 Results
from the European Community Respiratory
Health Survey (ECRHS) conducted in 1994
showed that for four British towns and cities, the
self-reported prevalence of ever having a diag-
nosis of hayfever or nasal allergy ranged from
23.6–29.2%.5
Whilst the above data provide useful infor-
mation on variations in lifetime/period preva-
lence of self-reported symptoms of allergic rhinitis
over time, particularly in children and adolescents,
relatively little reliable national data describes
clinician diagnosis of allergic rhinitis and changes
in the epidemiology for the whole adult popu-
lation over time. Exploitation of large national
healthcare datasets, with their key strengths of
large numbers and representative data, offers an
important opportunity to develop insights into the
epidemiology of allergic rhinitis and associated
prescribing.6
Studying primary care databases provides a
window onto overall national trends, something
that is not possible with large scale surveys such as
ISAAC (which has studied only children) and
ECRHS (which looks only at adults).7 Building on
our previous work,1,3,8 we sought to describe
recent trends in recorded primary care diagnosis
of allergic rhinitis and prescribing for allergic
rhinitis in England.
Methods
We used Version 10 of the QRESEARCH database,
which is a very large, nationally representative
anonymized aggregated health dataset derived
from 525 general practices throughout the UK.6 It
contains data for the period 1 January 1999 to 31
December 2005 and includes over 30 million
patient years of observation, these being derived
from over nine million individual patients. Only
practices from England were included in this
analysis. For further information on practice inclu-
sion and data collation, please refer to our initial
paper in this series of reports drawing on
QRESEARCH data.9
Patients were included in the analysis year if
they were registered for the entire analysis year in
question. Patients who might have incomplete
data (i.e. temporary residents, newly registered
patients and those who joined, left or died during
the year) were not eligible for inclusion. Data for a
total of 2,958,366 patients was analysed.
We considered patients to have allergic rhinitis
if they had a computer-recorded diagnostic Read
code for allergic rhinitis in their electronic health
record for the relevant time period. Details regard-
ing the Read codes used are available from the
corresponding author.
Incidence was defined as the number of new
cases of disease diagnosed and recorded in a
specific year, with the denominator of number of
patient years of observation (this being calculated
as a product of the number of patients registered
with practices and their length of registration)
being used to calculate incidence rates. Lifetime
prevalence was defined as the numbers of people
with a diagnosis of allergic rhinitis recorded in the
GP records on at least one occasion at any point
in their lives; the denominator used to calculate
the lifetime prevalence rate was the number of
patients registered with the study practices.
For the general population we have determined
the consultation rates per person per year with a
GP and with a nurse. This includes consultations
in the home, at the surgery and on the telephone.
We have also determined the consultation rate per
person per year for patients with each specific dis-
ease regardless of the reason for those consulta-
tions. Note that the requirements for patients to be
registered for thewhole of the analysis year lead to
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slight under-estimates of consultation rates in the
very young and the very elderly populations.10
Because of the known age and sex variations,
we standardized rates by sex and five-year age
bands using the estimated mid-year population
estimates for England in each year as our reference
population. These results were then scaled up to
estimate the actual numbers of peoplewith allergic
rhinitis in England. In order to better estimate the
actual numbers of people affected by allergic rhini-
tis, we calculated 95% confidence intervals around
these estimates of lifetime prevalence and absolute
numbers of people affected in 2005.11
In order to describe trends in prescribing of
antihistamines and nasal preparations of anti-
allergic medication, for each of the five years we
extracted linked prescribing data in those with a
recorded diagnosis of allergic rhinitis and esti-
mated numbers of prescriptions prescribed for
both antihistamines and other more specific drugs
used for the treatment of nasal allergy listed in
chapter 12.2.1 of the British National Formulary
(topical nasal corticosteroids, topical nasal anti-
histamines and topical nasal cromoglicate). Not all
patients issued prescriptions in general practice
actually present them to pharmacies for dispens-
ing; estimates based on issued prescriptions may
therefore be different from Prescribing Analysis
and Cost (PACT) data.
We used the Chi Square Mantel-Haenszel test
for trend using Epi Info software to test for trends
over time.12
Results
Age-sex standardization of lifetime
prevalence of allergic rhinitis and changes
over time
Figure 1 shows how the lifetime prevalence of
allergic rhinitis varied by age for both sexes in 2001
and 2005. There is a sharp increase in the lifetime
prevalence in males and females during the first
two decades of life, with peak lifetime prevalence
occurring in the 15–19 years age group. Thereafter
lifetime prevalence steadily declined in both sexes.
The highest lifetime prevalence rate was noted for
males aged 15–19 in 2005 at 105.1 per 1000 (95% CI
103.1 to 107.2 per 1000). Whilst lifetime prevalence
of allergic rhinitis was higher in males than in
females before the teenage prevalence peak, in the
years that follow, female prevalence exceeds that
of males.
Table 1 details the age–sex standardized life-
time prevalence rate of allergic rhinitis for each of
the five years of interest, showing a steady increase
in life time prevalence with an overall 43.2%
increase in recorded lifetime prevalence of allergic
rhinitis per 1000 patients over this time period.
The chi-square Mantel-Haenszel test was 12,352
(p<0.001) for lifetime prevalence, indicating a sig-
nificant positive trend from 2001–2005.
Incidence rate of allergic rhinitis and
changes over time
Table 2 details the incidence rate per 1000 person-
years of allergic rhinitis for each of the five years
of interest, these data showing an overall 33.0%
increase during the period 2001–2005. The Chi
Square Mantel-Haenszel test was 1110 (p<0.001)
for incidence rates, indicating a significant positive
trend from 2001–2005.
Consultation rates for allergic rhinitis
Table 3 details primary care consultation rates for
patients with allergic rhinitis (regardless of the
Figure 1
Lifetime prevalence of allergic rhinitis per 1000 patients.
© QRESEARCH 2006
Table 1
Lifetime prevalence (and 95% CI) of allergic rhinitis per 1000
registered patients, 2001–2005
Year Number of
patients with
allergic
rhinitis
All current
registered
patients
Age-sex
standardized
prevalence
rate per 1000
95%CI
2001 133,140 2,864,938 46.35 46.10–46.60
2002 147,739 2,890,190 50.97 50.71–51.23
2003 163,869 2,921,178 55.80 55.62–56.16
2004 180,193 2,922,024 61.40 61.12–61.69
2005 197,040 2,958,366 66.37 66.08–66.67
Journal of the Royal Society of Medicine
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reason for consultation) for each of the five years.
Figure 2 shows how consultation rates in patients
with allergic rhinitis compare with overall consul-
tation rates in 2005 regardless of the reason for
encounter. Consultation rates for females tended
to be higher than for males, and consultation rates
for patients with allergic rhinitis were higher than
overall consultation rates.
Figure 3 shows GP consultation rates per
patient (regardless of the reason for consultation)
for allergic rhinitis broken down by age and sex.
Trends in prescribing of antihistamines
and drugs used in nasal allergy
Table 4 details the estimated numbers of com-
munity prescriptions for antihistamines and drugs
used for nasal allergies in patients with allergic
rhinitis throughout England for each of the five
years. Overall, for these drugs there has been an
increase of 41.7% in the number of prescriptions
issued (antihistamines 45.5%, drugs used in nasal
allergies 35.5%).
Discussion
This study of routine data from one of the world’s
largest national datasets reveals a large, significant
increase in recorded incidence and lifetime preva-
lence of allergic rhinitis in primary care in England
during the period 2001–2005. This has been associ-
ated with an increase of similar proportion in the
issuing of prescriptions of prescribed treatments
for allergic rhinitis.
Considering findings in relation to the
published literature
Table 5 summarizes previous published epidemio-
logical data for allergic rhinitis. Data from our
work show that lifetime clinician-recorded preva-
lence peaks in the teenage years, and these results
are in keeping with data from latest ISAAC study
data.2 However, onemajor difference is the change
in prevalence of allergic rhinitis in teenagers
between these two studies. Whilst ISAAC Phase
Three shows a small fall in period prevalence from
Phase One for self-reported symptoms of allergic
rhinitis, our data show an increase in lifetime
prevalence for a recorded diagnosis of allergic
rhinitis. This discordance may reflect improved
diagnosis and recording. The female preponder-
ance for prevalence and increased consultation
rates for females after the teenage years has also
been identified in recent UK data describing
presentation of allergic rhinitis in primary care .13
The significant increases in recorded incidence
and lifetime prevalence of allergic rhinitis may
be multifactorial. There may have been recent
increased clinician awareness of allergic rhinitis,
which may then have led to improved identifi-
cation and recording of allergic rhinitis. Equally,
Table 2
Incidence rate (and 95% CI) of allergic rhinitis per 1000
patient-years, 2001–2005
Year Number of
patients
with a new
diagnosis
All current
registered
patients
Age-sex
standardized
incidence
rate/1000
person-years
95% CI
2001 15,709 2,864,938 5.57 5.48–5.66
2002 16,933 2,890,190 5.93 5.84–6.02
2003 18,287 2,921,178 6.35 6.26–6.45
2004 21,083 2,922,024 7.31 7.21–7.41
2005 21,516 2,958,366 7.41 7.31–7.51
Table 3
Consultation rates for allergic rhinitis (regardless of the reason for encounter) per patient by clinician
Year Clinician Number of consultations
by patients with allergic
rhinitis
Number of patients
with allergic rhinitis
Age-sex standardized
rate per person per
year
95% CI
2001 GP 493,655 133,140 4.00 3.98–4.01
Nurse 152,767 133,140 1.25 1.24–1.25
2002 GP 558,715 147,739 4.05 4.03–4.06
Nurse 186,572 147,739 1.36 1.36–1.37
2003 GP 640,681 163,869 4.19 4.18–4.20
Nurse 224,973 163,869 1.50 1.50–1.51
2004 GP 717,528 180,193 4.25 4.24–4.26
Nurse 263,127 180,193 1.58 1.57–1.59
2005 GP 793,227 197,040 4.26 4.25–4.27
Nurse 306,909 197,040 1.67 1.66–1.67
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patient awareness or parental awareness of the
potential of accessing effective treatments may
have resulted in increased case presentation in pri-
mary care. The increases may however also be due
to actual increases in the incidence and lifetime
prevalence of allergic rhinitis, this possibly reflect-
ing changing exposure to known and unknown
risk factors.14
Main strengths and limitations of this
work
The main strengths of this study include our inter-
rogation of an extremely large nationally represen-
Figure 2
Overall consultation rates compared with those for allergic
rhinitis, for all GP and nurse consultations in 2005. Includes
all consultations regardless of the reason for the encounter.
© QRESEARCH 2006
Figure 3
GP consultation rates per patient for allergic rhinitis.
© QRESEARCH 2006
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tative dataset, the fact that all contributing
practices used the same computing systems for
electronically recording clinical data and the
approach used to ensure that all contributing prac-
tices were accustomed to electronically recording
routine data. The study design means that it was
not subject to selection bias due to non-responders
or recall bias. Another strength of this study is the
use of clinician recording of a diagnosis of allergic
rhinitis, as opposed to self-reporting of symptoms
from previous studies.2,4,5 Although figures for
self-reporting of symptomsmay correlate to actual
prevalence, the role of a clinician assessing a
patient minimizes inappropriate diagnosis.
There are a number of limitations that need to
be considered when using databases of routinely
collected data and these all potentially apply to
this work. Most importantly, we were dependant
on physician-recorded diagnosis of allergic rhinitis
and there may have been improvements in record-
ing of allergic rhinitis over this time period. The
relatively short time window over which trends
were studied is another limitation, but this does
also have the advantage of confining analysis to a
period during which there were no changes in
disease definition or classification. Data regarding
childhood prevalence may be underestimated, as
clinician recording of diagnosis will be dependent
on parents bringing their children for consultation.
This is a recognized problem when using routine
general practice data for research, and has been
highlighted by previous research using general
practice data.15
Conclusions and implications for future
research
This large national study reveals that the recorded
incidence and lifetime prevalence of allergic rhini-
tis has increased in England during the first half of
this decade, which may reflect a genuine increase
in the incidence of allergic rhinitis. Given the find-
ings from a large recent UK case control study that
allergic rhinitis in adolescents is associated with
underperformance in summer school examina-
tions,16 a key important unanswered question con-
cerns the quality of care and symptom control
of these patients.17 The House of Lords Allergy
Inquiry, published in 2007, has identified several
issues highlighted by our work and other previous
research that require further attention.18 These
include: maintaining clinical surveillance systems
to monitor allergic disease; calling for further
research into the ways in which the indoor
environment influences allergy development;
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reviewing how children with allergic rhinitis are
supported throughout the examination system;
assessing the training that teachers receive in deal-
ing with allergic emergencies; assisting individ-
uals with occupational allergies to return to work.
These recommendations therefore need to be taken
seriously and acted on, to ensure that patients with
allergic rhinitis do not suffer unnecessarily.
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